Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.50 |
| ▸ | CPB1 | P15086 | 3/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427934 | 0.90 | PDE3B (0.54) | CPB2CPB1PDE3BPDE3AL3MBTL1 | |
| SCHEMBL7671977 | 0.85 | LTA4H (0.46) | CPB2CPB1PDE3BPDE3AL3MBTL1 | |
| SCHEMBL4424319 | 0.82 | CYP1A2 (0.49) | PDE3BPDE3AL3MBTL1NPC1RAB9A | |
| SCHEMBL3426575 | 0.81 | PDE3B (0.50) | CPB2CPB1PDE3BPDE3ANOTUM | |
| SCHEMBL4432563 | 0.81 | NOTUM (0.51) | CPB2CPB1PDE3BPDE3ANOTUM | |
| SCHEMBL27749290 | 0.81 | PDE3B (0.47) | CPB2CPB1PDE3BPDE3AL3MBTL1 | |
| SCHEMBL4428918 | 0.81 | PDE3B (0.53) | CPB2CPB1PDE3BPDE3ANOTUM | |
| SCHEMBL2173293 | 0.81 | PDE3B (0.50) | CPB2CPB1PDE3BPDE3ANOTUM | |
| SCHEMBL1698763 | 0.81 | PDE3B (0.50) | CPB2CPB1PDE3BPDE3AL3MBTL1 | |
| SCHEMBL4434213 | 0.81 | NOTUM (0.51) | CPB2CPB1PDE3BPDE3ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4443466-A | DIURETICS, SEDATIVES, ANALGESICS | Farmos-Yhtyma OY (Farmos Group Ltd.) (FI) | 1984-04-17 | — | — | US | claimed |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2023-12-21 | — | — | US | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20030187268-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-6610723-B2 | Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020151715-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002060877-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | WO | disclosed |
| US-6002005-A | Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 1999-12-14 | — | — | US | disclosed |
| US-5760234-A | THERAPY FOR NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| US-5750700-A | COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SCHIZOPHRENIA, NEUROLEPTIC AGENTS FOR BINDING TO DOPAMINE RECEPTORS | NEUROGEN CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| US-5478934-A | Treating central nervous system disorders | NEUROGEN CORPORATION | 1995-12-26 | — | — | US | disclosed |
| US-4443466-A | DIURETICS, SEDATIVES, ANALGESICS | Farmos-Yhtyma OY (Farmos Group Ltd.) (FI) | 1984-04-17 | — | — | US | disclosed |
| EP-0024829-A1 | 4-Benzyl- and 4-benzoylimidazole derivatives, processes for their preparation and pharmaceutical compositions comprising the same | Farmos-Yhtyma Oy (FI) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | CPB2 3741/4885CPB1 4092/4885PDE3B 3706/4885 |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | CPB2 3741/4885CPB1 4092/4885PDE3B 3706/4885 |
| US-20020151715-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | CPB2 4623/4885CPB1 4173/4885PDE3B 1701/4885 |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | CPB2 3741/4885CPB1 4092/4885PDE3B 3706/4885 |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC1, HDAC2 | CPB2 3231/4885CPB1 3463/4885PDE3B 4207/4885 |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | CPB2 1999/4885CPB1 1745/4885PDE3B 1527/4885 |
| US-20030187268-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | CPB2 4623/4885CPB1 4173/4885PDE3B 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.